结果表明,先前指定为PTCL CD30+CD15+的病例可能属于ALK阴性ALCL的谱系。 FIGURE 1 Morphologic features of ALCL, ALK- and PTCL CD30 + CD15+ cases. ALCL, ALK和PTCL CD30+CD15+在mRNA测序中基因表达无显著差异 FIGURE 2 ...
ALK阴性ALCL是一类CD30阳性T细胞淋巴瘤,其形态学与ALK阳性ALCL不能区分,不表达ALK蛋白,2008WHO列为临时疾病实体,但2017年版WHO已将其确立为正式疾病实体。ALK阴性ALCL必需与原发性皮肤ALCL、霍奇金淋巴瘤及其它具有间变特征或者表达CD30的T细胞或B细胞淋巴瘤亚型相鉴别。 诊断要点: 1.发病高峰年龄40-65岁,表现为进...
DUSP22、TP63在间变性淋巴瘤激酶(ALK)阴性的间变性大细胞淋巴瘤(ALK negative anaplastic large cell lymphoma,ALK-ALCL)中染色体易位与临床病理特征的关系,应用荧光原位杂交(FISH)技术检测ALK-ALCL病例DUSP22、TP63染色体易位情况;统计分析DUSP22和TP63染色体易位与...
Anaplastic Lymphoma Kinase (ALK)-negative systemic anaplastic large cell lymphoma presenting as zosteriform skin nodulesdoi:10.25259/IJDVL_1166_2022ANAPLASTIC large-cell lymphomaANAPLASTIC lymphoma kinaseCUTANEOUS T-cell lymphomaThis article discusses a case of anaplastic large cell lymp...
间变性大细胞淋巴瘤(Anaplastic large cell lymphoma,ALCL)分类: 1. 系统性ALK(Anaplastic lymphoma kinase, ALK)阳性ALCL:组织学亚型:普通型、淋巴组织细胞型、小细胞型、霍奇金样型、组合型 2. 系统性ALK阴性ALCL:分子学亚型:t(6;7)(p25.3;q32.3)/DUSP22/IRF4-FRA7H重排、TP63重排、Triple negative ...
(ALK)-negative ALCL and primary cutaneous ALCL.Although presenting with a similar morphological spectrum as ALK+ALCL, ALK−ALCL (15–50% of all systemic ALCL cases) was only defined as a provisional entity. In addition, ALK−ALCL usually occurs in comparatively older people and carries a ...
DUSP22-R ALK-negative ALCL is now defined as a genetic subtype of systemic ALK-negative ALCL ...
lymphoma;ALKnegativeanaplasticlargecelllymphoma;CD30 JExpHem a tol2011;19(2):511—516 ALK—ALCL隶属T细胞系淋巴瘤,其形态学 特征与ALK ALCL相似,肿瘤细胞一致表达 CD30,但ALK蛋白阴性,其流行病学特征及临床表 现具有高度的异质性,临床预后较ALKALCL差, ...
该病例最后诊断间变性淋巴瘤激酶(anaplasticlymphoma kinase,ALK)阴性的间变性大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL) ,即ALK-ALCL。让群里的所有老师感到十分意外并惊喜,意外的是没有人想到这个结果,而惊喜的是大家又一次大饱眼福沈老师的精彩病例,并且可以继续深入学习。根据现有的检查结果及沈老师的分析...
ALK-ALCL 是一种侵袭性T细胞淋巴瘤,发病率占外周T细胞淋巴瘤(PTCL)的5.5%。T细胞淋巴瘤计划(NCT01142674)是一项全球性前瞻性队列研究,2006年~2018年期间入组了1553例初诊断PTCL的患者(全球13个国家,74个中心),其中235例ALK阴性ALCL患者。 患者基线 ...